Search PubMed⌕ Search

Biomedical subjects

P E Van Schil

Publications and source records attributed to P E Van Schil.

At least 19 recordsLinked to original sources
PubMed2006

Surgery: therapeutic indications.

Although never proven to be superior in a large, prospective randomized trial, surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and resectable IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed. Standard operations include lobectomy, bilobectomy and pneumonectomy. Whenever possible, lobectomy is the procedure of choice. Lesser resections like segmentectomy or wedge excision are rarely indicated in primary NSCLC. Specific lung parenchyma saving operations include tracheo- and bronchoplastic procedures which are indicated in selected cases of centrally located NSCLC. Extended resections include removal of lung together with another organ or structure as thoracic wall, pericardium, diaphragm or superior sulcus. En bloc excision of the involved structure is advised. Accurate peroperative evaluation will determine the extent of resection and if possible, a pneumonectomy should be avoided because of its high mortality and morbidity rate. Surgical resection after induction therapy for early stage or locally advanced NSCLC is feasible, but is often more complex and carries a higher risk, especially when a right pneumonectomy has to be performed after induction chemoradiotherapy.

Carcinoma, Non-Small-Cell Lung↗
PubMed2005

Accuracy of duplex evaluation one year after varicose vein surgery to predict recurrence at the sapheno-femoral junction after five years.

OBJECTIVE: To investigate whether the results of duplex examination 1 year after sapheno-femoral junction (SFJ) ligation might be helpful in predicting long-term results after 5 years. PATIENTS AND METHODS: Follow-up data concerning patients operated on for primary or recurrent varicose veins of the great saphenous vein were studied 1 year and 5 years after surgery, focusing on the thigh and groin region. Clinical examination was undertaken to detect recurrent thigh varicose veins. The site of SFJ ligation was carefully screened for any signs of neovascularisation by duplex ultrasound. Sensitivity, specificity, positive and negative predictive value of the 1-year duplex scan were calculated, based upon the outcome of a further duplex scan 5 years following surgery. RESULTS: A total of 100 limbs were studied: 50 limbs operated on for primary varicose veins and 50 limbs for recurrent varicose veins. The 1-year duplex ultrasound of the SFJ ligation site had a sensitivity of 80%, a specificity of 91%, a positive predictive value of 70% and a negative predictive value of 95% in assessing the 5 year recurrence rate. CONCLUSION: A postoperative duplex scan of the SFJ 1 year after varicose vein surgery to the great saphenous vein predicts which patients are most likely to have a good outcome 5 years after surgery. The 1-year duplex scan is a reliable diagnostic tool for future studies evaluating the effect of new methods of treating sapheno-femoral incompetence.

Adult↗
PubMed2005

Current management of spontaneous pneumothorax.

Spontaneous pneumothorax is divided into primary, when there is no underlying lung disease, and secondary, mainly caused by chronic obstructive pulmonary disease. A variety of different non-invasive and invasive treatment options exist. Due to the lack of large randomised controlled trials no level A evidence is present. A first episode of a primary spontaneous pneumothorax is treated by observation if it is < 20% or by simple aspiration if it is > 20%, but recurrences are frequent. For recurrent or persisting pneumothorax a more invasive approach is indicated whereby video-assisted thoracic surgery provides a treatment of lung (resection of blebs or bullae) and pleura (pleurectomy or abrasion). In patients with a secondary spontaneous pneumothorax related to chronic obstructive pulmonary disease, there is an associated increased mortality and a more aggressive approach is warranted consisting of initial thoracic drainage followed by recurrence prevention by thoracoscopy or thoracotomy in patients with a low or moderate operative risk. Talc instillation by the thoracic drain is preferred for patients with a high operative risk.

Humans↗
PubMed2002

Can interposition of a silicone implant after sapheno-femoral ligation prevent recurrent varicose veins?

OBJECTIVES: To investigate whether a silicone implant at the sapheno-femoral ligation site could prevent recurrent varicosities. MATERIALS AND METHODS: Two non-randomised groups of patients were studied prospectively. In group A 173 patients and 212 limbs had sapheno-femoral ligation, while 172 patients and 210 limbs additionally had a piece (2x3cm) of silicone sheet sutured to the saphenous stump to cover the anterior half of the common femoral vein. The implant was fixed in apposition to the deep vein by carefully closing the cribriform fascia. Colour duplex scanning was performed after 2 and 12 months. RESULTS: In the no implant group neovascularisation was observed in 35 (17%) after 12 months, but only in 13 (6%) limbs treated with a silicone implant (p<0.05). CONCLUSIONS: Interposition of a partition of silicone implant seems to lower the incidence of neovascularisation one year after saphenofemoral ligation. This technique may constitute an efficient method to prevent recurrence at the correctly ligated saphenous stump.

Adult↗
PubMed2001

Surgery for non-small cell lung cancer.

Although never proven to be superior in a randomized trial, surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed. Standard operations include lobectomy, bilobectomy and pneumonectomy. Whenever possible, lobectomy is the procedure of choice. Lesser resections like segmentectomy or wedge excision are not indicated in primary NSCLC due to a higher local recurrence rate and poorer long-term survival. Specific lung parenchyma saving operations include tracheo- and bronchoplastic procedures which are indicated in selected cases of centrally located NSCLC. Extended resections include removal of lung together with another organ or structure as thoracic wall, pericardium, diaphragm or superior sulcus. En bloc excision of the involved structure is advised. Technically more demanding is lung resection after induction therapy, especially after combined chemoradiotherapy. A dense fibrotic reaction may render operative staging and dissection difficult. The precise, necessary extent of resection after induction therapy has not been determined yet. Although combined modality treatment has an overall increased morbidity and mortality rate, it may improve survival in selected cases of locally advanced NSCLC. Its precise role, however, still remains to be defined in large randomized trials.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed2000

Long-term results after bronchial sleeve resection.

In bronchial sleeve resections part of the bronchial wall is removed followed by the creation of a bronchial end-to-end anastomosis. The cylindrical part that is removed is called a "sleeve". In this way functional lung parenchyma can be saved in centrally located bronchogenic carcinomas while performing an oncologically valid operation. However, controversial results were reported in literature regarding long-term survival after bronchial sleeve resection especially in relation to nodal status. In a series of 145 patients undergoing bronchial sleeve resection for a bronchogenic tumor in the Antonius Hospital, Nieuwegein, the Netherlands, long-term results were studied. A univariate and multivariate analysis were performed to determine significant factors related to survival. Follow-up was updated until 1999, so a minimum follow-up of 10 years was obtained for surviving patients. For the entire group 5, 10 and 15-year survival rates were 45, 35 and 23%, respectively. Median survival time was 52 +/- 10 months. Five- and 10-year survival rates for the 71 patients with N0 disease were 62% and 53%, respectively; for the 58 patients with N1 disease, 29% and 21%; and for the 16 patients with N2 disease, 31% and 6%. There was a highly significant difference in survival between patients with N0 and N1 (p = 0.001) or N2 (p < 0.001) disease. The difference between N1 and N2 disease reached statistical significance (p = 0.047). A Cox multivariate regression analysis showed only nodal stage and patient age to be significant factors in relation to survival. To improve long-term survival adjuvant treatment should be considered in case of N1 or N2 disease as most of these patients die of distant metastases.

Adult↗
PubMed2000

Operative staging of lung cancer.

For earlier stage non-small cell lung cancer, surgical resection remains the most effective therapy. Complete resection of the primary tumour and lymph nodes should be the final aim in order to obtain the best long-term prognosis. Resectability depends on the tumour stage, and precise pre- and peroperative staging are of the utmost importance. In some cases, lung-sparing or extended operations are indicated. Despite modern scanning techniques, invasive staging by mediastinoscopy or thoracoscopy often remains necessary for determining resectability or deciding on a specific treatment. During thoracotomy, precise evaluation of the tumour and node factor is imperative for determining the extent of resection and achieving a complete tumour clearance. A systematic nodal dissection during thoracotomy is advised. Lung resection after induction therapy remains a technical challenge, especially after combined chemoradiotherapy. Peroperative staging is often difficult as distinction between viable tumour and fibrotic reaction is not easily made. Although combined modality treatment has an overall increased morbidity and mortality rate, it improves survival in selected cases of locally advanced non-small cell lung cancer.

Aged↗
PubMed1999

Bilateral pulmonary resection for lung metastases: report of two cases.

Resection of bilateral pulmonary metastases is exceptional. However, in carefully selected patients extensive resections might be successfully performed. We report two patients who underwent a pneumonectomy and excision of pulmonary metastases in the other lung, via a left wedge resection for patient 1 and left segmentectomy for patient 2. Resections were carried out for metastases of a malignant fibrous histyocytoma and for a teratocarcinoma. Both patients are still alive 9 months and 4 years after their last metastasectomy, respectively.

Adult↗
PubMed1999

Isolated lung perfusion with melphalan prolongs survival in a rat model of metastatic pulmonary adenocarcinoma.

INTRODUCTION: Survival after isolated lung perfusion (ILuP) with melphalan was tested in a model of unilateral pulmonary adenocarcinoma. METHODS: On day 0, rats were randomized into four groups: Group 1 (n = 9) received tumor cells intravenously for induction of bilateral lung metastases, whereas groups 2-4 (n = 21) underwent a 10-min occlusion of the right pulmonary artery during tumor cell injection for induction of unilateral left lung metastases. On day 7, groups 1 and 2 received no treatment. Group 3 underwent left ILuP with melphalan (2.0 mg/kg) while group 4 received melphalan intravenously (0.5 mg/kg). The end point of the study was death from metastatic disease. RESULTS: Median survival of ILuP-treated animals (81 +/- 12 days) was significantly longer compared to group 1 (18 +/- 1 days; p = 0.0001), group 2 (28 +/- 3 days; p = 0.0002) and group 4 (37 +/- 6; p = 0.0004). CONCLUSIONS: ILuP with melphalan prolongs survival in the treatment of experimental metastatic pulmonary carcinoma.

Adenocarcinoma↗
PubMed1999

Rebound thymic hyperplasia after chemotherapy in a patient treated for pulmonary metastases.

A 38-year-old patient presented with an anterior mediastinal mass after chemotherapeutic and surgical treatment for lung metastases from a malignant histiocytoma. Because of the risk for tumour recurrence the thymic mass was resected. Thymic hyperplasia was found on pathological examination. In this case thymic hyperplasia is a rebound phenomenon aflcer chemotherapy. It appears to atrophy during the administration of chemotherapy and regrow afterwards. Surgical resection provides the definitive diagnosis and treatment.

Adult↗
PubMed1998

Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma.

BACKGROUND: Isolated left lung perfusion with melphalan and human tumor necrosis factor-alpha for pulmonary metastatic adenocarcinoma in the WAG/Rij rat was studied. METHODS: Survival was determined for melphalan, human tumor necrosis-alpha. Lung, pulmonary effluent, and serum melphalan were analyzed by chromatography after isolated lung perfusion or intravenous injection. On day 0, rats were injected with 2.0 x 10(6) CC531S cells intravenously. On day 7, rats underwent sham thoracotomy, received melphalan intravenously, or underwent isolated left lung perfusion with saline, melphalan, tumor necrosis factor, and a combination of the latter two. On day 14, tumor nodules were counted. RESULTS: For the doses of 400 microg tumor necrosis factor, 1,000 microg tumor necrosis factor, or both melphalan and tumor necrosis factor (2 mg + 200 microg), survival rates after contralateral pneumonectomy were 33%, 17%, and 80%, respectively. Survival in all other groups was 100%. Left lung melphalan level was significantly higher after isolated lung perfusion compared to intravenous administration. Significantly fewer left lung nodules were found for 0.5 mg isolated lung perfusion with melphalan (28+/-17) compared to isolated administration (200+/-0) (p = 0.001), and for 1.0 mg intravenous lung perfusion with melphalan (16+/-10) compared to controls (171+/-65) (p = 0.00047). Tumor necrosis factor showed no significant effect. CONCLUSIONS: Isolated lung perfusion with melphalan is an effective treatment for pulmonary metastases from adenocarcinoma in the rat.

Adenocarcinoma↗